<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02125513</url>
  </required_header>
  <id_info>
    <org_study_id>GOGER-01</org_study_id>
    <secondary_id>2013-002520-17</secondary_id>
    <nct_id>NCT02125513</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer</brief_title>
  <acronym>GOGER-01</acronym>
  <official_title>Randomized Phase II Study of 3 vs 6 Courses of Neoadjuvant Carboplatin-paclitaxel Chemotherapy in Stage IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to define whether 6 courses of neoadjuvant chemotherapy can lead&#xD;
      to a higher rate of complete cytoreductive surgery compared with 3 courses of neoadjuvant&#xD;
      chemotherapy in patients with epithelial ovarian cancer, fallopian tube cancer or primary&#xD;
      peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who obtain a complete cytoreduction (no macroscopic residual tumor) at surgery , as a comparative outcome measure of 3 vs 6 courses of neoadjuvant chemotherapy</measure>
    <time_frame>within 6 weeks after the last cycle of chemotherapy</time_frame>
    <description>The primary objective of this study is to define whether 6 courses of neoadjuvant chemotherapy can lead to a higher rate of complete cytoreductive surgery compared with 3 courses of neoadjuvant chemotherapy in patients with bulky stage IIIC or IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with grade 3-5 perioperative toxicity (according to CTCAE), as a measure of safety</measure>
    <time_frame>within 30 days after surgery</time_frame>
    <description>To determine whether a longer duration of neoadjuvant chemotherapy is associated with a lower rate of perioperative grade 3-5 toxicities. The surgical adverse events are defined as:&#xD;
intraoperative, which occur during surgical procedure&#xD;
perioperative , which occur from day 1 to day 7 after surgery&#xD;
postoperative, which occur from day 8 to 30 days after surgery&#xD;
Adverse events list for surgical procedures:&#xD;
Postoperative death (&lt;30 days); Hemorrhage/bleeding intraoperative or postoperative requiring at least transfusion of 2 units of non-autologous red blood cells; Vascular events: thrombosis/embolism, disabling or life-threatening vessel injury-artery or vein, symptomatic or life-threatening visceral arterial ischemia; Infections requiring IV antibiotics, antifungal or antiviral interventions or at risk for life-threatening consequences; Gastrointestinal fistula; Urinary fistula; Lymphocele, requiring medical or operative intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with pathological complete response</measure>
    <time_frame>after surgery, up to 1 month after surgery</time_frame>
    <description>To determine whether a longer duration of neoadjuvant chemotherapy is associated with higher rate of pathological complete response.&#xD;
Complete pathological response is defined as the absence of cancer cells in surgical specimens, and very good partial remission is defined as the persistence of only small clusters (&lt; 1 cm) or individual cancer cells and no macroscopic residual after surgery. Partial pathological remission is defined as a tumor burden reduction between 30 and 90% at surgery, while stable disease is defined as no tumour burden reduction or reduction lower than 30% at surgery, compared with initial diagnostic laparoscopy. Only patients with complete and very good partial remissions are considered as pathological responders, while all the other cases are considered as pathological non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of progression-free survival</measure>
    <time_frame>from date of randomization until the date of disease progression or second cancer or death from any cause, whichever occurs first, assessed for 10 years after the end of chemotherapy</time_frame>
    <description>To determine whether a longer duration of neoadjuvant chemotherapy is associated with longer progression-free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>from baseline to safety follow-up visit (30-34 days after surgery)</time_frame>
    <description>To compare the quality of life in the two treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of radiological responses</measure>
    <time_frame>at the end of neoadjuvant chemotherapy, before surgery</time_frame>
    <description>To determine whether a longer duration of neoadjuvant chemotherapy is associated with a higher rate of radiological responses (according to RECIST 1.1 criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decrease of CA125 levels during NACT</measure>
    <time_frame>from cycle 1 of chemotherapy to safety follow-up visit (30-34 days after surgery)</time_frame>
    <description>To determine whether a longer duration of neoadjuvant chemotherapy is associated with a greater decrease of CA125 levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival</measure>
    <time_frame>from date of randomization until date of death due to any cause, assessed until 10 years after the end of chemotherapy</time_frame>
    <description>To determine whether a longer duration of neoadjuvant chemotherapy is associated with longer overall survival.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Carcinoma</condition>
  <condition>Peritoneal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: 3 courses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 3 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: 6 courses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 6 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin and paclitaxel followed by surgery</intervention_name>
    <arm_group_label>Arm A: 3 courses</arm_group_label>
    <arm_group_label>Arm B: 6 courses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients ≥18 years.&#xD;
&#xD;
          -  Karnofsky Performance Scale ≥ 60%&#xD;
&#xD;
          -  Histologically confirmed epithelial ovarian cancer, fallopian tube carcinoma or&#xD;
             primary peritoneal carcinoma with the exception of mucinous, clear cell, low-grade&#xD;
             carcinoma and carcinosarcoma histologies.&#xD;
&#xD;
          -  Documented International Federation of Gynecologic Oncology (FIGO) stage IIIC-IV&#xD;
             oligometastatic unsuitable for complete primary cytoreductive surgery. Inoperability&#xD;
             must be confirmed by open laparoscopy or by laparotomy.&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function to receive chemotherapy and&#xD;
             subsequently to undergo surgery:&#xD;
&#xD;
               -  white blood cells &gt;3,000/µL, absolute neutrophil count ≥1,500/µL, platelets&#xD;
                  ≥100,000/µL, hemoglobin ≥9 g/dL,&#xD;
&#xD;
               -  serum creatinine &lt;1.25 x upper normal limit (UNL) or creatinine clearance ≥60&#xD;
                  mL/min according to Cockroft-Gault formula or to local lab measurement&#xD;
&#xD;
               -  serum bilirubin &lt;1.25 x UNL, AST(SGOT) and ALT(SGPT) &lt;2.5 x UNL.&#xD;
&#xD;
          -  Signed informed consent obtained prior to any study-specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mucinous, clear cell, low-grade carcinoma and carcinosarcoma histologies.&#xD;
&#xD;
          -  Synchronous or previous other malignancies within 3 years prior to starting study&#xD;
             treatment, with the exception of adequately treated non-melanomatous skin cancer or&#xD;
             carcinoma in situ (of the cervix or breast or other sites).&#xD;
&#xD;
          -  Patients with brain metastases, seizure not controlled with standard medical therapy,&#xD;
             or history of cerebrovascular accident (CVA, stroke) or transient ischemic attack&#xD;
             (TIA) or subarachnoid hemorrhage within 6 months from the enrollment on this study.&#xD;
&#xD;
          -  Any other concurrent medical conditions contraindicating surgery or chemotherapy that&#xD;
             could compromise the adherence to the protocol (including but not limited to impaired&#xD;
             cardiac function or clinically significant cardiac diseases, active or uncontrolled&#xD;
             infections, HIV-positive patients on antiretroviral therapy, uncontrolled diabetes,&#xD;
             cirrhosis, chronic active or persistent hepatitis, impaired respiratory function&#xD;
             requiring oxygen-dependence,serious psychiatric disorders).&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Zamagni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S.Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Zamagni, MD</last_name>
      <phone>+390516364548</phone>
      <email>claudio.zamagni@aosp.bo.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Zamagni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierandrea De Iaco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma - Oncologia Medica</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Bella, MD</last_name>
      <email>mbella@ao.pr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Aguzzoli, MD</last_name>
      <email>Lorenzo.Aguzzoli@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Aguzzoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Scambia, MD</last_name>
      <email>giovanni.scambia@policlinicogemelli.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Santa Maria della Misericordia di Udine, Reparto di Oncologia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cosimo Sacco, MD</last_name>
      <phone>0432 559330</phone>
      <phone_ext>+39</phone_ext>
      <email>cosimo.sacco@asuiud.sanita.fvg.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2014</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Claudio Zamagni MD</investigator_full_name>
    <investigator_title>MD Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>fallopian tube carcinoma</keyword>
  <keyword>peritoneal carcinoma</keyword>
  <keyword>randomized study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

